Clinical Trials Logo

AIDS-related Kaposi Sarcoma clinical trials

View clinical trials related to AIDS-related Kaposi Sarcoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05567601 Not yet recruiting - Multiple Myeloma Clinical Trials

Doxil/Caelyx BE Study

Start date: November 30, 2023
Phase: Phase 1
Study type: Interventional

The aim of this study is to demonstrate the bioequivalence of DOXIL/CAELYX, 40 mg/m2 (IV infusion over 90 minutes) between two manufacturing facilities. According to the Food and Drug Administration (FDA), two products are considered to be bioequivalent when they are equal in the rate and extent to which the active pharmaceutical ingredient (API) becomes available at the site(s) of drug action. Any abnormalities of the safety endpoints (Clinical Laboratory Test, Electrocardiogram, Left Ventricular Ejection Fraction, Physical Examination) will be captured as Adverse Events.

NCT ID: NCT05411237 Not yet recruiting - HIV-1-infection Clinical Trials

Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma

Start date: March 15, 2024
Phase: Phase 3
Study type: Interventional

This study is being done to determine if two different anti-cancer drugs, paclitaxel (PTX) and pegylated liposomal doxorubicin (PLD) have similar effects on treating Kaposi Sarcoma (KS) in people living with HIV (human immunodeficiency virus) in sub-Saharan Africa. Patients with HIV-related KS will receive either PTX or PLD once every 3 weeks for a total of six cycles.